Apogee therapeutics announces first participants dosed in phase 1 clinical trial of apg990, its novel half-life extended ox40l antibody for the treatment of atopic dermatitis and other inflammatory diseases

Interim safety and pharmacokinetic data from phase 1 healthy volunteers trial anticipated in 2025 initiation of the first clinical trial of apg777 and apg990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across i&i diseases san francisco and waltham, mass., aug. 19, 2024 (globe newswire) -- apogee therapeutics, inc., (nasdaq: apge), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (i&i) markets, including for the treatment of atopic dermatitis (ad), asthma, chronic obstructive pulmonary disease (copd) and other i&i indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for apg990, a novel, subcutaneous (sq) half-life extended monoclonal antibody targeting ox40l, which is being developed initially as a treatment for people living with ad.
APG Ratings Summary
APG Quant Ranking